RBM15 in diseases: Molecular mechanisms and clinical opportunities from RNA m⁶A methylation

Area of Science:

• Molecular Biology
• Epigenetics
• Genetics

Background:

• RNA N⁶-methyladenosine (m⁶A) is a prevalent epigenetic modification impacting RNA function.
• RBM15 acts as a key 'writer' enzyme, catalyzing m⁶A methylation on RNA molecules.
• RBM15-mediated m⁶A modification influences RNA stability, translation, and gene expression.

Purpose of the Study:

• To review current research on RBM15's role in m⁶A methylation.
• To explore RBM15's molecular mechanisms in diseases, including cancer and metabolic disorders.
• To discuss RBM15 as a potential therapeutic target for gene therapy.

Main Methods:

• Literature review of recent studies on RBM15 and m⁶A methylation.
• Analysis of RBM15's involvement in disease pathogenesis.
• Evaluation of RBM15-targeted therapeutic strategies.

Main Results:

• RBM15 critically regulates gene expression through m⁶A modification.
• Dysregulation of RBM15 is implicated in various diseases, notably cancer and metabolic diseases.
• The m⁶A methylation process mediated by RBM15 presents a promising therapeutic avenue.

Conclusions:

• RBM15 is a vital regulator of RNA m⁶A methylation with significant implications in disease.
• Understanding RBM15's function provides insights into disease mechanisms.
• Targeting RBM15 offers potential for novel therapeutic interventions and gene therapy strategies.